Sam van Bohemen, Co-Founder, CEO and CTO of Nuroflux based.
Nuroflux is the world’s first wearable to non-invasively monitor brain activity and blood flow alongside other vital activity relevant to stroke and stroke rehabilitation.
[00:08 – 01:26] Sam van Bohemen
Hi, my name is Sam and I am the CEO and co-founder of Nuroflux.
When a family member suffered multiple strokes in between CT scans, we were desperate to understand why these strokes were not detected. And now, at Nuroflux, we are developing an innovative device to address this problem.
Worldwide, there is a stroke every 2 seconds, and with an ageing population, the incidence of stroke is expected to increase.
Following a suspected stroke, a patient will come into a hospital where they will have a CT scan to confirm the diagnosis. Now CT scans provide an imaging snapshot in time, but due to radiation exposure are only performed every 24 hours. In this first 24 hour window, patients will receive treatment and are at risk of deterioration, such as having a secondary stroke, which occurs in 10% of all patients. However, there is currently no way to continuously monitor patients’ brain activity and brain blood flow, which are key indicators in stroke. Standard care relies upon waiting for the next CT scan and on nurses performing intensive nursing observations. Now, as you can imagine, this is very distressing for patients and is time consuming for nurses. It is the subject of a method and is useless if the patient is unconscious.
At Nuroflux we are developing a wearable device that will provide real time continuous monitoring of treatment and the detection of patient deterioration, leading to faster detection intervention and improved patient outcome. Our wearable device utilizes a proprietary, multi-modal system that I have developed during my PhD in biomedical engineering to provide real time continuous monitoring of brain activity and brain blood flow simultaneously, the device will be easy to use and will have alert algorithms that indicate the need for clinical action, such as the detection of secondary strokes, the neurological and diagnostic and monitoring equipment market is growing. In fact, the Asia-Pacific region is experiencing the largest growth in the sector. However, we anticipate our device will also disrupt the global diagnostic imaging market, which is valued at 37 billion AUD.
Our initial foothold market will be in-hospital monitoring where we will sell devices and offer a subscription service for our software platform. However, there are also a number of exciting expansion opportunities.
Our device is scalable to ambulances and at home settings to help detect stroke in the community and due to the low cost and portable nature of the device. We’re also interested in rural and remote communities where there is limited access to CT and MRI scanners. Furthermore, our device may also monitor other diseases, including delirium and traumatic brain injury.
David and I are the co-founders of Nuroflux. I’m a biomedical engineering Ph.D. student with a neuroscience honors degree. My co-founder, David, is a commercialization and innovation associate and a major medical research institute. He has a PhD in medicine and is completing his MBA. We are also supported by an experienced team of clinical, and strategic advisors. Nuroflux has also formed an exciting strategic partnership with the George Institute for Global Health, a Medical Research Institute to pursue a multicenter clinical efficacy trial that will take place in Sydney and will be supported by three of Australia’s leading stroke clinicians.
We are seeking $800,000 at a $4.1 million pre money valuation. These funds will help secure our IP position, develop our regulatory strategy and create our next generation device and software platform. We are seeking pre-seed investment and strategic partners.
If you have any questions, please feel free to reach out. We hope that you will join us on our journey to improve stroke patient outcomes in Australia and worldwide.